MARY KATHRYN EDWARDS: Open Payments
NPI 1174096853 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,552 in 91 payments from 22 companies in 2025. Trend: 2023 $1,412 · 2024 $1,430 · 2025 $1,552
Food & beverage: $1,552
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $237 |
| AstraZeneca Pharmaceuticals LP | 7 | $175 |
| ABBVIE INC. | 15 | $166 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $156 |
| Lilly USA, LLC | 4 | $74 |
| Amgen Inc. | 4 | $70 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Astellas Pharma US Inc | 3 | $53 |
Products named: Kerendia, CAPLYTA, Rybelsus, AIRSUPRA, VRAYLAR, Ozempic, MOUNJARO, NEXLETOL.
Industry payments across LA — which companies pay providers there.
